{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:39:01Z","timestamp":1785537541240,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03972-4","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:41:00Z","timestamp":1763984460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Keratin 80 serves as a potential biomarker in metastatic breast cancer"],"prefix":"10.1007","volume":"16","author":[{"given":"Feng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"1","key":"3972_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"3972_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/cac2.12025","volume":"40","author":"M Cao","year":"2020","unstructured":"Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in china: A need for sustainable actions. Cancer Commun (London England). 2020;40(5):205\u201310. https:\/\/doi.org\/10.1002\/cac2.12025.","journal-title":"Cancer Commun (London England)"},{"issue":"11","key":"3972_CR3","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1007\/s11427-022-2240-6","volume":"66","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yan Q, Fan C, Mo Y, Wang Y, Li X, et al. Overview and countermeasures of cancer burden in China. Sci China Life Sci. 2023;66(11):2515\u201326. https:\/\/doi.org\/10.1007\/s11427-022-2240-6.","journal-title":"Sci China Life Sci"},{"key":"3972_CR4","doi-asserted-by":"publisher","unstructured":"Calar K, Plesselova S, Bhattacharya S, Jorgensen M, de la Puente P. Human Plasma-Derived 3D cultures model breast cancer treatment responses and predict clinically effective drug treatment concentrations. Cancers. 2020;12(7). https:\/\/doi.org\/10.3390\/cancers12071722.","DOI":"10.3390\/cancers12071722"},{"issue":"2","key":"3972_CR5","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/bib\/bbaa026","volume":"22","author":"S Wang","year":"2021","unstructured":"Wang S, Zhang Q, Yu C, Cao Y, Zuo Y, Yang L. Immune cell infiltration-based signature for prognosis and Immunogenomic analysis in breast cancer. Brief Bioinform. 2021;22(2):2020\u201331. https:\/\/doi.org\/10.1093\/bib\/bbaa026.","journal-title":"Brief Bioinform"},{"issue":"4","key":"3972_CR6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.20892\/j.issn.2095-3941.2020.0028","volume":"17","author":"N Vargas-Rondon","year":"2020","unstructured":"Vargas-Rondon N, Perez-Mora E, Villegas VE, Rondon-Lagos M. Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines. Cancer Biology Med. 2020;17(4):970\u201385. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0028.","journal-title":"Cancer Biology Med"},{"issue":"5","key":"3972_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.celrep.2015.09.063","volume":"13","author":"B Han","year":"2015","unstructured":"Han B, Qu Y, Jin Y, Yu Y, Deng N, Wawrowsky K, et al. FOXC1 activates Smoothened-Independent Hedgehog signaling in Basal-like breast cancer. Cell Rep. 2015;13(5):1046\u201358. https:\/\/doi.org\/10.1016\/j.celrep.2015.09.063.","journal-title":"Cell Rep"},{"key":"3972_CR8","doi-asserted-by":"publisher","unstructured":"Bhattarai S, Sugita BM, Bortoletto SM, Fonseca AS, Cavalli LR, Aneja R. QNBC is associated with high genomic instability characterized by copy number alterations and MiRNA deregulation. Int J Mol Sci. 2021;22(21). https:\/\/doi.org\/10.3390\/ijms222111548.","DOI":"10.3390\/ijms222111548"},{"issue":"3","key":"3972_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clbc.2019.01.006","volume":"19","author":"K Maajani","year":"2019","unstructured":"Maajani K, Jalali A, Alipour S, Khodadost M, Tohidinik HR, Yazdani K. The global and regional survival rate of women with breast cancer: A systematic review and Meta-analysis. Clin Breast Cancer. 2019;19(3):165\u201377. https:\/\/doi.org\/10.1016\/j.clbc.2019.01.006.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"3972_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-022-01260-0","volume":"15","author":"M Liao","year":"2022","unstructured":"Liao M, Qin R, Huang W, Zhu HP, Peng F, Han B, et al. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 2022;15(1):44. https:\/\/doi.org\/10.1186\/s13045-022-01260-0.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3972_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.apsb.2019.03.006","volume":"9","author":"D Mei","year":"2019","unstructured":"Mei D, Chen B, He B, Liu H, Lin Z, Lin J, et al. Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer. Acta Pharm Sin B. 2019;9(5):1061\u201377. https:\/\/doi.org\/10.1016\/j.apsb.2019.03.006.","journal-title":"Acta Pharm Sin B"},{"issue":"10087","key":"3972_CR12","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","volume":"389","author":"C Denkert","year":"2017","unstructured":"Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(16)32454-0.","journal-title":"Lancet"},{"key":"3972_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-0-387-74039-3_1","volume":"608","author":"AM Gonzalez-Angulo","year":"2007","unstructured":"Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1\u201322. https:\/\/doi.org\/10.1007\/978-0-387-74039-3_1.","journal-title":"Adv Exp Med Biol"},{"key":"3972_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2025.07.015","author":"Y Li","year":"2025","unstructured":"Li Y, Li D, Tao X, Ye Y, Zhang C, Xu Z, et al. Integrated prognostic model for young breast cancer patients: insights from SEER, METABRIC, and TCGA databases. Clin Breast Cancer. 2025. https:\/\/doi.org\/10.1016\/j.clbc.2025.07.015.","journal-title":"Clin Breast Cancer"},{"key":"3972_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2147\/BCTT.S523199","volume":"17","author":"S Song","year":"2025","unstructured":"Song S, Sun L, Liu X, Zhang L, Li C, Liu Z, et al. Clinical prognosis and nomograms for hormone receptor-Positive and human epidermal growth factor receptor 2-Negative metastatic breast cancer patients treated with Palbociclib and endocrine therapy. Breast Cancer (Dove Med Press). 2025;17:669\u201381. https:\/\/doi.org\/10.2147\/BCTT.S523199.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"6","key":"3972_CR16","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1016\/j.clbc.2025.05.004","volume":"25","author":"JN Zhang","year":"2025","unstructured":"Zhang JN, Zhou XR, Yi ZL, Tian XY, Liu H. The construction of a new prognostic model of breast cancer and the exploration of drug sensitivity based on machine learning for Glycosylation-Related genes. Clin Breast Cancer. 2025;25(6):e756\u201364. https:\/\/doi.org\/10.1016\/j.clbc.2025.05.004.","journal-title":"Clin Breast Cancer"},{"key":"3972_CR17","doi-asserted-by":"publisher","unstructured":"Li K, Tan G, Zhang X, Lu W, Ren J, Si Y, et al. EIF4G1 is a potential prognostic biomarker of breast cancer. Biomolecules. 2022;12(12). https:\/\/doi.org\/10.3390\/biom12121756.","DOI":"10.3390\/biom12121756"},{"key":"3972_CR18","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3389\/fgene.2019.01390","volume":"10","author":"P Xie","year":"2019","unstructured":"Xie P, Ma Y, Yu S, An R, He J, Zhang H. Development of an Immune-Related prognostic signature in breast cancer. Front Genet. 2019;10:1390. https:\/\/doi.org\/10.3389\/fgene.2019.01390.","journal-title":"Front Genet"},{"issue":"1","key":"3972_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12885-021-07837-1","volume":"21","author":"W Tan","year":"2021","unstructured":"Tan W, Liu M, Wang L, Guo Y, Wei C, Zhang S, et al. Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer. BMC Cancer. 2021;21(1):126. https:\/\/doi.org\/10.1186\/s12885-021-07837-1.","journal-title":"BMC Cancer"},{"key":"3972_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinformatics"},{"issue":"7","key":"3972_CR21","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"3972_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"issue":"4","key":"3972_CR23","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/bioinformatics\/btu684","volume":"31","author":"G Yu","year":"2015","unstructured":"Yu G, Wang LG, Yan GR, He QY. DOSE: an R\/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics. 2015;31(4):608\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btu684.","journal-title":"Bioinformatics"},{"issue":"D1","key":"3972_CR24","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607\u201313. https:\/\/doi.org\/10.1093\/nar\/gky1131.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"3972_CR25","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504. https:\/\/doi.org\/10.1101\/gr.1239303.","journal-title":"Genome Res"},{"issue":"30","key":"3972_CR26","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1002\/sim.5958","volume":"32","author":"P Blanche","year":"2013","unstructured":"Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381\u201397. https:\/\/doi.org\/10.1002\/sim.5958.","journal-title":"Stat Med"},{"key":"3972_CR27","doi-asserted-by":"publisher","unstructured":"Maeser D, Gruener RF, Huang RS. OncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6). https:\/\/doi.org\/10.1093\/bib\/bbab260.","DOI":"10.1093\/bib\/bbab260"},{"key":"3972_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-023-00880-2","author":"J Li","year":"2023","unstructured":"Li J, Yao J, Qi L. Identification of TUBB2A as a cancer-Immunity Cycle-Related therapeutic target in Triple-Negative breast cancer. Mol Biotechnol. 2023. https:\/\/doi.org\/10.1007\/s12033-023-00880-2.","journal-title":"Mol Biotechnol"},{"issue":"1","key":"3972_CR29","doi-asserted-by":"publisher","first-page":"e2925","DOI":"10.1002\/iub.2925","volume":"77","author":"R Hua","year":"2025","unstructured":"Hua R, Yan X, He J, Wu N, Yu W, Yu P, et al. KRT80 in hepatocellular carcinoma plays oncogenic role via epithelial-mesenchymal transition and PI3K\/AKT pathway. IUBMB Life. 2025;77(1):e2925. https:\/\/doi.org\/10.1002\/iub.2925.","journal-title":"IUBMB Life"},{"issue":"8","key":"3972_CR30","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.7150\/jca.91753","volume":"15","author":"S Huang","year":"2024","unstructured":"Huang S, Tong W, Yang B, Ma L, Zhang J, Wang C, et al. KRT80 promotes lung adenocarcinoma progression and serves as a substrate for VCP. J Cancer. 2024;15(8):2229\u201344. https:\/\/doi.org\/10.7150\/jca.91753.","journal-title":"J Cancer"},{"key":"3972_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pharmthera.2016.03.003","volume":"161","author":"Z Li","year":"2016","unstructured":"Li Z, Kang Y. Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther. 2016;161:79\u201396. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.03.003.","journal-title":"Pharmacol Ther"},{"issue":"13","key":"3972_CR32","doi-asserted-by":"publisher","first-page":"13991","DOI":"10.1002\/cam4.6040","volume":"12","author":"XY Wei","year":"2023","unstructured":"Wei XY, Zhao J, Tong HB, Cheng SJ, He N, Song FX. Characters of KRT80 and its roles in neoplasms diseases. Cancer Med. 2023;12(13):13991\u20134003. https:\/\/doi.org\/10.1002\/cam4.6040.","journal-title":"Cancer Med"},{"issue":"11","key":"3972_CR33","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/s10038-020-0795-x","volume":"65","author":"M Wada","year":"2020","unstructured":"Wada M, Goto Y, Tanaka T, Okada R, Moriya S, Idichi T, et al. RNA sequencing-based MicroRNA expression signature in esophageal squamous cell carcinoma: oncogenic targets by antitumor miR-143-5p and miR-143-3p regulation. J Hum Genet. 2020;65(11):1019\u201334. https:\/\/doi.org\/10.1038\/s10038-020-0795-x.","journal-title":"J Hum Genet"},{"issue":"1","key":"3972_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41420-022-00839-3","volume":"8","author":"S Ouyang","year":"2022","unstructured":"Ouyang S, Zeng Z, Liu Z, Zhang Z, Sun J, Wang X, et al. OTUB2 regulates KRT80 stability via deubiquitination and promotes tumour proliferation in gastric cancer. Cell Death Discov. 2022;8(1):45. https:\/\/doi.org\/10.1038\/s41420-022-00839-3.","journal-title":"Cell Death Discov"},{"issue":"10","key":"3972_CR35","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41419-018-1030-y","volume":"9","author":"C Li","year":"2018","unstructured":"Li C, Liu X, Liu Y, Liu X, Wang R, Liao J, et al. Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway. Cell Death Dis. 2018;9(10):1009. https:\/\/doi.org\/10.1038\/s41419-018-1030-y.","journal-title":"Cell Death Dis"},{"key":"3972_CR36","doi-asserted-by":"publisher","unstructured":"Wu YF, Wang CY, Tang WC, Lee YC, Ta HDK, Lin LC, et al. Expression profile and prognostic value of Wnt signaling pathway molecules in colorectal cancer. Biomedicines. 2021;9(10). https:\/\/doi.org\/10.3390\/biomedicines9101331.","DOI":"10.3390\/biomedicines9101331"},{"issue":"22","key":"3972_CR37","doi-asserted-by":"publisher","first-page":"6835","DOI":"10.7150\/jca.64031","volume":"12","author":"O Liu","year":"2021","unstructured":"Liu O, Wang C, Wang S, Hu Y, Gou R, Dong H, et al. Keratin 80 regulated by miR-206\/ETS1 promotes tumor progression via the MEK\/ERK pathway in ovarian cancer. J Cancer. 2021;12(22):6835\u201350. https:\/\/doi.org\/10.7150\/jca.64031.","journal-title":"J Cancer"},{"issue":"1","key":"3972_CR38","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1038\/s41467-019-09676-y","volume":"10","author":"Y Perone","year":"2019","unstructured":"Perone Y, Farrugia AJ, Rodriguez-Meira A, Gyorffy B, Ion C, Uggetti A, et al. SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERalpha breast cancer. Nat Commun. 2019;10(1):2115. https:\/\/doi.org\/10.1038\/s41467-019-09676-y.","journal-title":"Nat Commun"},{"issue":"11","key":"3972_CR39","doi-asserted-by":"publisher","first-page":"111178","DOI":"10.1016\/j.isci.2024.111178","volume":"27","author":"Y Xie","year":"2024","unstructured":"Xie Y, Liu Z, Zhang J, Li G, Ni B, Shi C, et al. Deciphering the composition and key driver genes of breast invasive micropapillary carcinoma by multi-omics analysis. iScience. 2024;27(11):111178. https:\/\/doi.org\/10.1016\/j.isci.2024.111178.","journal-title":"iScience"},{"issue":"2","key":"3972_CR40","doi-asserted-by":"publisher","first-page":"e0227768","DOI":"10.1371\/journal.pone.0227768","volume":"15","author":"J Lu","year":"2020","unstructured":"Lu J, Zang H, Zheng H, Zhan Y, Yang Y, Zhang Y, et al. Overexpression of p-Akt, p-mTOR and p-eIF4E proteins associates with metastasis and unfavorable prognosis in non-small cell lung cancer. PLoS ONE. 2020;15(2):e0227768. https:\/\/doi.org\/10.1371\/journal.pone.0227768.","journal-title":"PLoS ONE"},{"key":"3972_CR41","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12957-015-0746-8","volume":"13","author":"L Xiaoping","year":"2015","unstructured":"Xiaoping L, Xiaowei Z, Leizhen Z, Weijian G. Expression and significance of CD44 and p-AKT in pancreatic head cancer. World J Surg Oncol. 2015;13:334. https:\/\/doi.org\/10.1186\/s12957-015-0746-8.","journal-title":"World J Surg Oncol"},{"issue":"7","key":"3972_CR42","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41419-023-05972-0","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y, Wang Y, Zhang Y, Ye F, Luo D, Li Y, et al. HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-kappaB signaling pathway in breast cancer. Cell Death Dis. 2023;14(7):434. https:\/\/doi.org\/10.1038\/s41419-023-05972-0.","journal-title":"Cell Death Dis"},{"issue":"18","key":"3972_CR43","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2217\/pgs-2017-0044","volume":"18","author":"YH Park","year":"2017","unstructured":"Park YH. The nuclear factor-kappa B pathway and response to treatment in breast cancer. Pharmacogenomics. 2017;18(18):1697\u2013709. https:\/\/doi.org\/10.2217\/pgs-2017-0044.","journal-title":"Pharmacogenomics"},{"key":"3972_CR44","doi-asserted-by":"publisher","first-page":"152925","DOI":"10.1016\/j.phymed.2019.152925","volume":"64","author":"P Liu","year":"2019","unstructured":"Liu P, Lu Z, Liu L, Li R, Liang Z, Shen M, et al. NOD-like receptor signaling in inflammation-associated cancers: from functions to targeted therapies. Phytomedicine. 2019;64:152925. https:\/\/doi.org\/10.1016\/j.phymed.2019.152925.","journal-title":"Phytomedicine"},{"issue":"6","key":"3972_CR45","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.3892\/ol.2016.5263","volume":"12","author":"L Peng","year":"2016","unstructured":"Peng L, Hu Y, Chen D, Linghu R, Wang Y, Kou X, et al. Ubiquitin specific protease 21 upregulation in breast cancer promotes cell tumorigenic capability and is associated with the NOD-like receptor signaling pathway. Oncol Lett. 2016;12(6):4531\u20137. https:\/\/doi.org\/10.3892\/ol.2016.5263.","journal-title":"Oncol Lett"},{"key":"3972_CR46","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975.","journal-title":"EBioMedicine"},{"key":"3972_CR47","doi-asserted-by":"publisher","first-page":"689727","DOI":"10.3389\/fcell.2021.689727","volume":"9","author":"Y Fu","year":"2021","unstructured":"Fu Y, Peng Y, Zhao S, Mou J, Zeng L, Jiang X, et al. Combination foretinib and Anti-PD-1 antibody immunotherapy for colorectal carcinoma. Front Cell Dev Biol. 2021;9:689727. https:\/\/doi.org\/10.3389\/fcell.2021.689727.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"3972_CR48","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes Anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731\u2013e4313. https:\/\/doi.org\/10.1016\/j.cell.2018.10.014.","journal-title":"Cell"},{"key":"3972_CR49","doi-asserted-by":"publisher","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812\u2009\u2013\u200930 e14. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023","DOI":"10.1016\/j.immuni.2018.03.023"},{"key":"3972_CR50","doi-asserted-by":"publisher","first-page":"1334886","DOI":"10.3389\/fimmu.2023.1334886","volume":"14","author":"X Meng","year":"2023","unstructured":"Meng X, Xu H, Liang Y, Liang M, Song W, Zhou B, et al. Enhanced CT-based radiomics model to predict natural killer cell infiltration and clinical prognosis in non-small cell lung cancer. Front Immunol. 2023;14:1334886. https:\/\/doi.org\/10.3389\/fimmu.2023.1334886.","journal-title":"Front Immunol"},{"key":"3972_CR51","doi-asserted-by":"publisher","unstructured":"Hou YC, Chao YJ, Hsieh MH, Tung HL, Wang HC, Shan YS. Low CD8(+) T cell infiltration and high PD-L1 expression are associated with level of CD44(+)\/CD133(+) cancer stem cells and predict an unfavorable prognosis in pancreatic cancer. Cancers. 2019;11(4). https:\/\/doi.org\/10.3390\/cancers11040541.","DOI":"10.3390\/cancers11040541"},{"issue":"1","key":"3972_CR52","doi-asserted-by":"publisher","first-page":"e0279775","DOI":"10.1371\/journal.pone.0279775","volume":"18","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Liu X, Cai Y, Li W. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review. PLoS ONE. 2023;18(1):e0279775. https:\/\/doi.org\/10.1371\/journal.pone.0279775.","journal-title":"PLoS ONE"},{"issue":"2","key":"3972_CR53","doi-asserted-by":"publisher","first-page":"100433","DOI":"10.1016\/j.esmoop.2022.100433","volume":"7","author":"V Guarneri","year":"2022","unstructured":"Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, Girardi F. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. ESMO Open. 2022;7(2):100433. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100433.","journal-title":"ESMO Open"},{"issue":"6","key":"3972_CR54","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1002\/tox.24202","volume":"39","author":"CY Ho","year":"2024","unstructured":"Ho CY, Wei CY, Zhao RW, Ye YL, Huang HC, Lee JC, et al. Artemisia argyi extracts overcome lapatinib resistance via enhancing TMPRSS2 activation in HER2-positive breast cancer. Environ Toxicol. 2024;39(6):3389\u201399. https:\/\/doi.org\/10.1002\/tox.24202.","journal-title":"Environ Toxicol"},{"key":"3972_CR55","doi-asserted-by":"publisher","unstructured":"Leis-Filho AF, de Faria Lainetti P, Emiko Kobayashi P, Fonseca-Alves CE, Laufer-Amorim R. Effects of lapatinib on HER2-Positive and HER2-Negative canine mammary carcinoma cells cultured in vitro. Pharmaceutics. 2021;13(6). https:\/\/doi.org\/10.3390\/pharmaceutics13060897.","DOI":"10.3390\/pharmaceutics13060897"},{"issue":"2","key":"3972_CR56","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/wjs.12480","volume":"49","author":"K Tamai","year":"2025","unstructured":"Tamai K, Tei M, Tsujimura N, Nishida K, Mori S, Yoshikawa Y, et al. Impact of small tumor size on prognosis in T3N1 colon cancer. World J Surg. 2025;49(2):343\u201352. https:\/\/doi.org\/10.1002\/wjs.12480.","journal-title":"World J Surg"},{"key":"3972_CR57","doi-asserted-by":"publisher","unstructured":"Tomasicchio G, Mastropasqua MG, Picciariello A, Montanaro AE, Signorile D, Cirilli A, et al. A new possible Cut-Off of cytokeratin 19 mRNA copy number by OSNA in the Sentinel node of breast cancer patients to avoid unnecessary axillary dissection: A 10-Year experience in a tertiary breast unit. Cancers. 2022;14(14). https:\/\/doi.org\/10.3390\/cancers14143384.","DOI":"10.3390\/cancers14143384"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03972-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03972-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03972-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:41:00Z","timestamp":1763984460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03972-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3972"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03972-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was not required in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2158"}}